Am J Cancer Res 2025;15(11):4815-4817
www.ajcr.us /ISSN:2156-6976/ajcr0167805

Erratum
IL-6 derived from therapy-induced senescence facilitates the glycolytic phenotype in glioblastoma cells: Am J Cancer Res. 2021; 11(2): 458-478

Jiayu Gu[1,2,3*], Jingyi Wang[1*], Xincheng Liu[1*], Ke Sai[4,5], Jialuo Mai[1], Fan Xing[1], Zhijie Chen[4], Xiaozhi Yang[1], Wanjun Lu[1], Cui Guo[1], Wenfeng Liu[1], Yang Xu[1], Shouxia Xie[2,3], Cheng Hu[1], Guangmei Yan[1], Wenbo Zhu[1]

[1]Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China; [2]Department of Pharmacy, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China; [3]The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China; [4]Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; [5]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. [*]Equal contributors.

Received July 30, 2025; Accepted August 18, 2025; Epub November 25, 2025; Published November 30, 2025

An error has been identified in **Figure 2**: during figure assembly, the panel in **Figure 2C** showing the β-Galactosidase (β-Gal) activity of U87 cells after 1 day of dbcAMP treatment was inadvertently presented with the same image as the control group. Accordingly, we have corrected and replaced the image for the 1-day dbcAMP treatment panel in **Figure 2C** (U87 cells) in the revised **Figure 2**. This change to the representative image does not affect the interpretation of **Figure 2**. The error has no bearing on the interpretation of the results nor does it influence the conclusions of the study. The authors sincerely apologize for any confusion or concern this error may have caused. The corrected **Figure 2** is enclosed.

Address correspondence to: Dr. Wenbo Zhu, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou 510080, Guangdong, China. Tel: +86-20-87333258; Fax: +86-20-87330578; E-mail: zhuwenbo@mail.sysu.edu.cn

https://doi.org/10.62347/ATCD4291


A
Con
D1
D2
D3
D4
28.12%
21.63%
19.68%
9.83%
0.49%
DBTRG
25.91%
26.59%
16.56%
8.39%
0.25%
U87
EdU
DAPI
B
EDU positive cell(%)
Con
D1
D2
D3
D4
DBTRG
U87
C
dbcAMP
DBTRG
U87
250 μm
D
SA-β-gal positive cell(%)
E
H3K9me3
Histone H2A.X (phospho S139)
Histone H2A.X
DEC1
HMGB1
β-actin
F
p16
p21
CDK2
CDK4
CDK6
CyclinE
CyclinD1
pRb
Rb
β-actin



Figure 2. cAMP activation induces the senescence of cultured GBM cell lines and patient-derived GBM cells. (A, B) Proportion of EdU-positive DBTRG and U87cells. (C) The bright-field images of β-Gal activity staining. Cells with blue staining were considered senescent. Scale bar, 250 μm. (D) The statistical data of SA-β-gal-positive cells. (E) Protein expression of senescence biomarkers, including H3K9me3, histone H2A.X (phosphorylated S139), total H2A.X, DEC1 and HMGB1, in DBTRG and U87 cells, as detected by western blot analysis. (F) Expression of proteins involved in senescence-inducing pathways, including p16, p21, CDK2, CDK4, CDK6, cyclin E, and cyclin D1, phosphorylated and total Rb in DBTRG and U87 cells, as detected by western blot analysis. (G) The bright-field images of β-Gal activity staining. Cells with blue staining were considered senescent. Scale bar, 250 μm. DBTRG cells, U87 cells and primary patient-derived GBM cells were treated with 1 mM dbcAMP for 1, 2,3 and 4 days and then subjected to FCM (A), β-gal activity staining analysis (C and G), and western blot analysis (E and F).